Sapere Bio, Inc. focuses on leveraging advanced computational technologies to enhance drug discovery and development processes. The company employs a unique platform that integrates machine learning and artificial intelligence to analyze complex biological data. This approach enables the identification of novel therapeutic targets and the optimization of drug candidates, ultimately accelerating the timeline from discovery to clinical application. By harnessing vast datasets, Sapere Bio aims to improve the precision and efficacy of treatments, particularly in the fields of oncology and rare diseases.

In addition to its computational capabilities, Sapere Bio emphasizes the importance of biological insights in its technology. The company combines high-throughput screening and genomic analysis to validate its computational predictions, ensuring that the identified targets are biologically relevant. This dual approach not only enhances the reliability of their findings but also fosters a deeper understanding of disease mechanisms. Through this innovative integration of technology and science, Sapere Bio is positioned to make significant contributions to the pharmaceutical industry and improve patient outcomes.

United States

Sapere Bio is a longevity technology company. SapereX, a blood-based measure of cellular senescence and immune function, captures fundamental mechanisms of aging. SapereX allows clinicians and scientists to see early aging and monitor how interventions aimed to increase healthspan are working in individual patients.  We are changing the way aging is measured and imagined, for longer healthspan and better lives.

Sapere Bio was co-founded by Dr. Norman Sharpless, former Director of the NCI, and Dr Natalia Mitin, current CEO of Sapere Bio.

Sapere Bio, Inc.

Company Details